MANILA, Philippines — The Mall of Asia Arena (MOA) has installed a brand new centerhung, an upgrade on the original jumbotron that hung at the venue since 2012. The installation of the "The Cube ...

for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

MoA Core Bond Fund earns an Above Average Process Pillar rating. The most important driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

for FILSPARI (sparsentan). The FDA has scheduled a Prescription Drug User Fee Act (PDUFA) target action date for January 13, 2026, and plans to convene an advisory committee meeting to discuss the ...

Stocks must pass the index committee’s liquidity, size, and profitability screens. The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be ...

for traditional approval of FILSPARI® (sparsentan), a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target ...

It was joined earlier this year by Travere Therapeutics’ Filspari (sparsentan), another ERA drug. We’re back this year, this time virtually attending the FT US Pharma and Biotech Summit in New ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

In its continuing efforts to offer meaningful and holistic experiences for mallgoers, SM Mall of Asia (MOA), in partnership with the Miraculous Medal Apostolate, the Archdiocesan Commission on Liturgy ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of ...